Screener
Castle Biosciences CSTL Business Segments — Equity Securities, FV-NI, Gain (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.
The source filing: Castle Biosciences’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:09 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012272
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Interest income | $11,772 | $12,916 | $10,623 |
| Interest expense | $86 | $577 | $11 |
| Depreciation and amortization | $40,771 | $15,997 | $12,330 |
| Income tax (benefit) expense | $(5,356) | $3,319 | $101 |
| Stock-based compensation expense | $45,893 | $50,320 | $51,219 |
| Net gains on equity securities | $1,466 | $555 | — |
Item 16. Form 10-K Summary.
FAQ
- What is Castle Biosciences's business segments — equity securities, FV-NI, gain (loss)?
- Castle Biosciences (CSTL) reported business segments — equity securities, FV-NI, gain (loss) of $366.5K in Q4 2025.
- How has Castle Biosciences's business segments — equity securities, FV-NI, gain (loss) changed year-over-year?
- Castle Biosciences's business segments — equity securities, FV-NI, gain (loss) increased by 164.1% year-over-year, from $138.75K to $366.5K.
- What does business segments — equity securities, FV-NI, gain (loss) mean?
- This measures the total gains or losses recognized in the income statement resulting from changes in the fair value of equity securities held by the segment. It highlights the financial performance of the segment's investment portfolio relative to market conditions.
Ask your AI about Castle Biosciences's business segments — equity securities, fv-ni, gain (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude